These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...

Halozyme Therapeutics, Inc. (NASDAQ:HALO) is a biopharmaceutical company focused on innovative drug delivery technologies, primarily through its Enhaze platform. This technology, based on the rHuPH20 ...

Novartis is buying Anthos Therapeutics from Blackstone’s drug development division, as it makes a bet on an experimental drug aimed at preventing strokes in patients with an irregular heart rhythm.

We think the strategy to find more effective combination therapies in hematology and build a larger oncology and dermatology portfolio is solid, although we're waiting for key data before assuming the ...

M&A in biotech and pharma is expected to surge in late 2024 as regulatory uncertainties ease. Discover trends, key players, and areas of high interest.

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Greenwich LifeSciences (GLSI – Research Report) ...

Novartis is buying Anthos Therapeutics from Blackstone’s drug development division, as it makes a bet on an experimental drug aimed at preventing strokes in patients with an irregular heart rhythm.

The IXP Lifesciences Catalyst Fund has a greenshoe option of Rs 100 crore with an investment horizon of 3-5 years targeting ...

The portfolio will comprise 20-25 B2B startups spanning Pre-seed to Series A stages, addressing innovation gaps in areas such as pharmaceuticals, biotechnology, medical technology, specialty chemicals ...